Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 8 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Global Markets Direct Report Coverage | 10 | 1 |
| Refractory Chronic Lymphocytic Leukemia (CLL) Overview | 11 | 1 |
| Therapeutics Development | 12 | 2 |
| Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) Overview | 12 | 1 |
| Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) Comparative Analysis | 13 | 1 |
| Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics under Development by Companies | 14 | 2 |
| Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics under Investigation by Universities/Institutes | 16 | 1 |
| Refractory Chronic Lymphocytic Leukemia (CLL) Pipeline Products Glance | 17 | 3 |
| Late Stage Products | 17 | 1 |
| Clinical Stage Products | 18 | 1 |
| Early Stage Products | 19 | 1 |
| Refractory Chronic Lymphocytic Leukemia (CLL) Products under Development by Companies | 20 | 3 |
| Refractory Chronic Lymphocytic Leukemia (CLL) Products under Investigation by Universities/Institutes | 23 | 1 |
| Refractory Chronic Lymphocytic Leukemia (CLL) Companies Involved in Therapeutics Development | 24 | 30 |
| 4SC AG | 24 | 1 |
| AbbVie Inc | 25 | 1 |
| Arno Therapeutics, Inc. | 26 | 1 |
| Astellas Pharma Inc. | 27 | 1 |
| Astex Pharmaceuticals Inc | 28 | 1 |
| Boehringer Ingelheim GmbH | 29 | 1 |
| Bristol-Myers Squibb Company | 30 | 1 |
| Celgene Corporation | 31 | 1 |
| Cellular Biomedicine Group, Inc. | 32 | 1 |
| F. Hoffmann-La Roche Ltd. | 33 | 1 |
| Gilead Sciences, Inc. | 34 | 1 |
| Hutchison MediPharma Limited | 35 | 1 |
| ImmunoGen, Inc. | 36 | 1 |
| Immunomedics, Inc. | 37 | 1 |
| Incyte Corporation | 38 | 1 |
| Innate Pharma S.A. | 39 | 1 |
| Juno Therapeutics Inc. | 40 | 1 |
| Karyopharm Therapeutics, Inc. | 41 | 1 |
| LFB S.A. | 42 | 1 |
| Lymphocyte Activation Technologies, S.A. | 43 | 1 |
| Medicenna Therapeutics, Inc. | 44 | 1 |
| Millennium Pharmaceuticals Inc | 45 | 1 |
| MorphoSys AG | 46 | 1 |
| Novartis AG | 47 | 1 |
| Oncternal Therapeutics, Inc. | 48 | 1 |
| Ono Pharmaceutical Co., Ltd. | 49 | 1 |
| Portola Pharmaceuticals, Inc. | 50 | 1 |
| Sanofi | 51 | 1 |
| Tragara Pharmaceuticals, Inc. | 52 | 1 |
| Verastem, Inc. | 53 | 1 |
| Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Assessment | 54 | 12 |
| Assessment by Monotherapy Products | 54 | 1 |
| Assessment by Combination Products | 55 | 1 |
| Assessment by Target | 56 | 3 |
| Assessment by Mechanism of Action | 59 | 3 |
| Assessment by Route of Administration | 62 | 2 |
| Assessment by Molecule Type | 64 | 2 |
| Drug Profiles | 66 | 184 |
| (dezapelisib + itacitinib adipate) Drug Profile | 66 | 1 |
| 4SC-202 Drug Profile | 67 | 2 |
| acalabrutinib Drug Profile | 69 | 3 |
| ACP-319 Drug Profile | 72 | 1 |
| afuresertib hydrochloride Drug Profile | 73 | 3 |
| AGS-67E Drug Profile | 76 | 2 |
| AR-42 Drug Profile | 78 | 2 |
| AT-7519 Drug Profile | 80 | 3 |
| atezolizumab Drug Profile | 83 | 14 |
| BI-836826 Drug Profile | 97 | 2 |
| BMS-986016 Drug Profile | 99 | 2 |
| buparlisib hydrochloride Drug Profile | 101 | 5 |
| CBM-C19.1 Drug Profile | 106 | 1 |
| CBM-C20.1 Drug Profile | 107 | 2 |
| CC-122 Drug Profile | 109 | 2 |
| Cellular Immunotherapy for Chronic Lymphocytic Leukaemia Drug Profile | 111 | 1 |
| Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia Drug Profile | 112 | 1 |
| cerdulatinib Drug Profile | 113 | 3 |
| duvelisib Drug Profile | 116 | 10 |
| HMPL-523 Drug Profile | 126 | 2 |
| idelalisib Drug Profile | 128 | 8 |
| IMGN-529 Drug Profile | 136 | 2 |
| IMMU-114 Drug Profile | 138 | 2 |
| JCAR-014 Drug Profile | 140 | 3 |
| JCAR-015 Drug Profile | 143 | 4 |
| lirilumab Drug Profile | 147 | 4 |
| MDNA-56 Drug Profile | 151 | 1 |
| monalizumab Drug Profile | 152 | 3 |
| MOR-208 Drug Profile | 155 | 5 |
| nivolumab Drug Profile | 160 | 26 |
| obinutuzumab Drug Profile | 186 | 7 |
| PCAR-019 Drug Profile | 193 | 1 |
| PCAR-119 Drug Profile | 194 | 1 |
| pilaralisib Drug Profile | 195 | 3 |
| S-055746 Drug Profile | 198 | 1 |
| selinexor Drug Profile | 199 | 19 |
| spebrutinib besylate Drug Profile | 218 | 2 |
| TAK-659 Drug Profile | 220 | 1 |
| TG-02 Drug Profile | 221 | 3 |
| tisagenlecleucel-T Drug Profile | 224 | 5 |
| ublituximab Drug Profile | 229 | 7 |
| UC-961 Drug Profile | 236 | 2 |
| ulocuplumab Drug Profile | 238 | 1 |
| urelumab Drug Profile | 239 | 2 |
| venetoclax Drug Profile | 241 | 9 |
| Refractory Chronic Lymphocytic Leukemia (CLL) Dormant Projects | 250 | 2 |
| Refractory Chronic Lymphocytic Leukemia (CLL) Discontinued Products | 252 | 1 |
| Refractory Chronic Lymphocytic Leukemia (CLL) Product Development Milestones | 253 | 12 |
| Featured News &Press Releases | 253 | 1 |
| Apr 18, 2016: Immunomedics Announces Potent Anti-Tumor Activities with IMMU-114 in Preclinical Study in Acute and Chronic Leukemia | 253 | 1 |
| Jan 20, 2016: Abbvie's Venetoclax Receives Breakthrough Therapy Designation From FDA In Combination With Rituximab For The Treatment Of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia | 253 | 1 |
| Nov 05, 2015: Genentech to Present New Clinical Data From Venetoclax at American Society of Hematology 2015 Annual Meeting | 254 | 1 |
| Jun 12, 2015: Phase 1b Study of Investigational Treatment Venetoclax With Rituximab Shows Clinical Response in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia | 255 | 1 |
| Jun 11, 2015: TG Therapeutics to Present Clinical Data on TG-1101 in combination with ibrutinib at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma | 256 | 1 |
| May 11, 2015: Abbvie To Present New Data From Studies Of Duvelisib Assets In Multiple Cancers At The 51st American Society Of Clinical Oncology Annual Meeting | 256 | 1 |
| May 06, 2015: Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation In Relapsed Or Refractory Chronic Lymphocytic Leukemia In Previously Treated Patients With The 17P Deletion Genetic Mutation | 257 | 1 |
| Dec 05, 2014: Roche to present clinical data on obinutuzumab at ASH | 257 | 1 |
| Nov 06, 2014: Infinity Announces Clinical and Preclincal Data for Duvelisib to Be Presented at ASH 2014 Annual Meeting | 258 | 1 |
| May 31, 2014: AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting | 259 | 1 |
| Apr 23, 2014: Abbvie To Present Data On ABT-199 At The 2014 American Society Of Clinical Oncology Annual Meeting | 260 | 1 |
| Dec 03, 2013: MorphoSys Strengthens European Patent Position on anti-CD19 Cancer Program MOR208 | 260 | 1 |
| Oct 22, 2013: MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208 | 261 | 1 |
| Oct 07, 2013: MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 | 261 | 1 |
| Jun 17, 2013: AbbVie Presents Preliminary Results From Phase I Study Of ABT-199/GDC-0199 In Patients With High-Risk CLL At EHA Annual Meeting | 262 | 3 |
| Appendix | 265 | 2 |
| Methodology | 265 | 1 |
| Coverage | 265 | 1 |
| Secondary Research | 265 | 1 |
| Primary Research | 265 | 1 |
| Expert Panel Validation | 265 | 1 |
| Contact Us | 265 | 1 |
| Disclaimer | 266 | 1 |